- Home
- SLQT vs CAPR Comparison
SLQT vs CAPR Comparison
Compare SLQT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- CAPR
- Stock Information
- Founded
- SLQT 1999
- CAPR 2005
- Country
- SLQT United States
- CAPR United States
- Employees
- SLQT N/A
- CAPR N/A
- Industry
- SLQT Specialty Insurers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLQT Finance
- CAPR Health Care
- Exchange
- SLQT Nasdaq
- CAPR Nasdaq
- Market Cap
- SLQT 343.7M
- CAPR 322.7M
- IPO Year
- SLQT 2020
- CAPR N/A
- Fundamental
- Price
- SLQT $1.93
- CAPR $7.96
- Analyst Decision
- SLQT Hold
- CAPR Strong Buy
- Analyst Count
- SLQT 2
- CAPR 8
- Target Price
- SLQT $4.38
- CAPR $24.75
- AVG Volume (30 Days)
- SLQT 1.2M
- CAPR 1.9M
- Earning Date
- SLQT 08-21-2025
- CAPR 08-11-2025
- Dividend Yield
- SLQT N/A
- CAPR N/A
- EPS Growth
- SLQT N/A
- CAPR N/A
- EPS
- SLQT N/A
- CAPR N/A
- Revenue
- SLQT $1,488,701,000.00
- CAPR $13,392,150.00
- Revenue This Year
- SLQT $17.27
- CAPR $16.24
- Revenue Next Year
- SLQT $13.23
- CAPR $328.11
- P/E Ratio
- SLQT N/A
- CAPR N/A
- Revenue Growth
- SLQT 20.41
- CAPR N/A
- 52 Week Low
- SLQT $1.62
- CAPR $3.84
- 52 Week High
- SLQT $6.86
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- SLQT 44.59
- CAPR 48.47
- Support Level
- SLQT $1.90
- CAPR $7.60
- Resistance Level
- SLQT $2.14
- CAPR $8.60
- Average True Range (ATR)
- SLQT 0.13
- CAPR 0.64
- MACD
- SLQT 0.03
- CAPR 0.15
- Stochastic Oscillator
- SLQT 56.25
- CAPR 47.87
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.